179 related articles for article (PubMed ID: 30209247)
21. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
22. Unusual cause of hypercalcaemia in end stage renal failure patients.
Teo HK; Wong J
Hemodial Int; 2017 Apr; 21(2):E40-E44. PubMed ID: 27866377
[TBL] [Abstract][Full Text] [Related]
23. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
[TBL] [Abstract][Full Text] [Related]
24. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
25. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Adhikaree J; Newby Y; Sundar S
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
[No Abstract] [Full Text] [Related]
26. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M; Ishiguro H; Yano I; Toi M
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
[No Abstract] [Full Text] [Related]
27. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.
Alos N; Eugène D; Fillion M; Powell J; Kokta V; Chabot G
Horm Res; 2006; 65(6):289-94. PubMed ID: 16612105
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Coleman RE
Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
[TBL] [Abstract][Full Text] [Related]
29. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
30. Update on the medical treatment of hypercalcemia of malignancy.
Hall TG; Schaiff RA
Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
[TBL] [Abstract][Full Text] [Related]
31. Tumor induced hypercalcemia in a patient with mediastinal synovial sarcoma.
Vakili R; Hiradfar M; Zabolinejad N; Badiei Z
J Pediatr Endocrinol Metab; 2007 Jul; 20(7):841-5. PubMed ID: 17849748
[TBL] [Abstract][Full Text] [Related]
32. Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study.
Macro M; Bouvard G; Le Gangneux E; Colin T; Loyau G
Rev Rhum Engl Ed; 1995 Feb; 62(2):99-104. PubMed ID: 7600079
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
34. Childhood cancer and hypercalcemia: report of a case treated with pamidronate.
Kutluk MT; Hazar V; Akyüz C; Varan A; Büyükpamukçu M
J Pediatr; 1997 May; 130(5):828-31. PubMed ID: 9152297
[TBL] [Abstract][Full Text] [Related]
35. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Nikolic-Tomasević Z; Jelic S; Popov I; Radosavljević D; Mitrović L
Oncology; 2001; 60(2):123-6. PubMed ID: 11244326
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children.
Demir K; Döneray H; Kara C; Atay Z; Çetinkaya S; Çayır A; Anık A; Eren E; Uçaktürk A; Can Yılmaz G; Törel Ergür A; Kendirci M; Aycan Z; Bereket A; Aydın M; Orbak Z; Özkan B
J Clin Res Pediatr Endocrinol; 2019 May; 11(2):140-148. PubMed ID: 30396880
[TBL] [Abstract][Full Text] [Related]
38. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
39. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
40. Use of high-dose denosumab in the management of immobilization-related hypercalcemia in an end-stage renal disease patient on hemodialysis: A case report and review of the literature.
Zaitoun MF; Al-Alsheikh KA; Elnazer W
Clin Nephrol; 2021 Dec; 96(6):353-356. PubMed ID: 34605398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
